Bionano GenomicsBNGO
BNGO
About: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Employees: 100
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.5% less ownership
Funds ownership: 5.96% [Q4 2024] → 5.46% (-0.5%) [Q1 2025]
29% less capital invested
Capital invested by funds: $1.75M [Q4 2024] → $1.25M (-$503K) [Q1 2025]
42% less funds holding
Funds holding: 52 [Q4 2024] → 30 (-22) [Q1 2025]
85% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 26
96% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 25
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
10%
upside
Avg. target
$7.33
101%
upside
High target
$10
174%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Maxim Group Jason McCarthy | 119%upside $8 | Buy Upgraded | 20 May 2025 |
HC Wainwright & Co. Yi Chen | 174%upside $10 | Buy Initiated | 9 Apr 2025 |
Scotiabank Sung Ji Nam | 10%upside $4 | Sector Perform Maintained | 2 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs from third party payers.
Neutral
Seeking Alpha
1 month ago
Bionano Genomics, Inc. (BNGO) Q1 2025 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Vivian Alhorn - BTIG Joanne Lee - Maxim Group Operator Good day, and welcome to the Bionano First Quarter 2025 Earnings Conference Call. Today's conference is being recorded.
Neutral
GlobeNewsWire
1 month ago
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit.
Neutral
GlobeNewsWire
1 month ago
Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies
In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs) In 15% or 75 of 519 cases, OGM identified additional Tier 1 variants with detection rates varying by disease type, ranging from 52% in T-ALL to 0% in MPN. Every Tier 1 SV or CNV detected by OGM had direct diagnostic, prognostic, or therapeutic significance, meaning that the detection would provide additional clinical utility SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced a publication from The University of Texas MD Anderson Cancer Center describing the largest study to-date to evaluate the clinical utility of OGM as an additional tool in the standard cytogenetic workup (SCGW) of hematologic malignancies.
Neutral
GlobeNewsWire
1 month ago
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress.
Neutral
GlobeNewsWire
1 month ago
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced the publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping (ICOGM) for the integration of OGM as a standard-of-care (SOC) cytogenetic assay for diagnostic workflows in various clinical settings. Nineteen (19) experts from the ICOGM, representing relevant multidisciplinary fields, conducted an in-depth review of the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.
Neutral
GlobeNewsWire
1 month ago
Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud University Medical Center in the Netherlands, the study provides one of the most comprehensive evaluations to date of OGM as a single workflow for characterizing large repeat expansions.
Neutral
GlobeNewsWire
2 months ago
Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM, can be problematic because it is challenging to isolate enough cells with a known MM marker (CD138) on their surface, so-called CD138-positive cells. In this paper, researchers at Institute of Medical Genetics, Lille University Hospital, Lille, France, have described a method for OGM that can overcome the hurdle of limited sample quantity and can cut in half the effective CD138-positive cell requirement for analysis by OGM.
Neutral
Seeking Alpha
2 months ago
Bionano Genomics, Inc. (BNGO) Q4 2024 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Operator Good day, and welcome to the Bionano Fourth Quarter 2024 Earnings Conference Call. Today's conference is being recorded.
Neutral
GlobeNewsWire
2 months ago
Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025. “2024 has been an important year for Bionano.
Charts implemented using Lightweight Charts™